Skip to content
Disclosery

ETRA ELECTRA THERAPEUTICS INC

Follow

Common Stock, $0.0001 par value per share (common), issuer CIK 2088082

Filings received so far for Q3 2026: 1 13F filer report a position in ETRA shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.

13D and 13G filers

Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.

Insider trades

No Form 4 transaction on this security in the data.

13F holders, Q3 2026

Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.

HolderSharesValue% of portfolioChangeSource
Y-Intercept (Hong Kong) Ltd21,103$237K0.01%new13F-HRTimeline

Events

  • Redmile Group, LLC and 2 other reporting persons reported 5,462,881 ETRA shares, 8.7% of the class, as of 2026-09-21, in a 13G filed 2026-09-28. 0001104659-26-111478

    Accepted , ingested

  • LSP 7 Cooperatief U.A. and 1 other reporting person reported 3,795,281 ETRA shares, 6% of the class, as of 2026-09-21, in a 13G filed 2026-09-28. 0001193125-26-405752

    Accepted , ingested

  • ORBIMED ADVISORS LLC and 2 other reporting persons reported 6,885,170 ETRA shares, 11% of the class, as of 2026-09-21, in a 13D filed 2026-09-25. 0000947871-26-000898

    Accepted , ingested